Is NeoGenomics (NASDAQ:NEO) Now a Sell? How Analysts Rate it and Why BTIG Downgraded The Stock

September 13, 2017 - By Clifton Ray

 Is NeoGenomics (NASDAQ:NEO) Now a Sell? How Analysts Rate it and Why BTIG Downgraded The Stock

Investors sentiment decreased to 1.15 in 2016 Q4. Its down 0.10, from 1.25 in 2016Q3. It is negative, as 11 investors sold NeoGenomics, Inc. shares while 44 reduced holdings. 19 funds opened positions while 44 raised stakes. 58.46 million shares or 2.70% more from 56.93 million shares in 2016Q3 were reported.

California State Teachers Retirement holds 109,330 shares or 0% of its portfolio. Tiaa Cref Investment Management Llc reported 151,808 shares or 0% of all its holdings. 2,950 were accumulated by Ruggie Cap Group. Blair William Il stated it has 0.02% in NeoGenomics, Inc. (NASDAQ:NEO). Rmb Capital Mngmt Limited Liability Corporation invested 0.85% in NeoGenomics, Inc. (NASDAQ:NEO). Kopp Invest Ltd Co has 4.39% invested in NeoGenomics, Inc. (NASDAQ:NEO). Blackrock Gp holds 0% of its portfolio in NeoGenomics, Inc. (NASDAQ:NEO) for 44,534 shares. Emerald Advisers Pa holds 977,256 shares or 0.36% of its portfolio. 13,516 are owned by Legal & General Group Public Ltd Liability Corporation. Fifth Third Bankshares accumulated 0% or 4,000 shares. Campbell Investment Adviser Ltd reported 13,590 shares or 0.36% of all its holdings. State Common Retirement Fund reported 595,427 shares. Nationwide Fund Advsr accumulated 33,848 shares. Cortina Asset Mgmt Ltd Company accumulated 0.44% or 1.22 million shares. Blackrock Advsr Lc owns 0% invested in NeoGenomics, Inc. (NASDAQ:NEO) for 28,528 shares.

Since May 25, 2017, it had 0 insider purchases, and 2 insider sales for $574,394 activity. The insider BALLIET JENNIFER sold $25,005.

NeoGenomics (NASDAQ:NEO) Receives a Downgrade

BTIG decreased the rating on NeoGenomics (NASDAQ:NEO) shares to a Hold. This, change in their rating was just sent to investors and clients in a research note earlier today.

Investors sentiment decreased to 1.15 in 2016 Q4. Its down 0.10, from 1.25 in 2016Q3. It is negative, as 11 investors sold NeoGenomics, Inc. shares while 44 reduced holdings. 19 funds opened positions while 44 raised stakes. 58.46 million shares or 2.70% more from 56.93 million shares in 2016Q3 were reported.

California State Teachers Retirement holds 109,330 shares or 0% of its portfolio. Tiaa Cref Investment Management Llc reported 151,808 shares or 0% of all its holdings. 2,950 were accumulated by Ruggie Cap Group. Blair William Il stated it has 0.02% in NeoGenomics, Inc. (NASDAQ:NEO). Rmb Capital Mngmt Limited Liability Corporation invested 0.85% in NeoGenomics, Inc. (NASDAQ:NEO). Kopp Invest Ltd Co has 4.39% invested in NeoGenomics, Inc. (NASDAQ:NEO). Blackrock Gp holds 0% of its portfolio in NeoGenomics, Inc. (NASDAQ:NEO) for 44,534 shares. Emerald Advisers Pa holds 977,256 shares or 0.36% of its portfolio. 13,516 are owned by Legal & General Group Public Ltd Liability Corporation. Fifth Third Bankshares accumulated 0% or 4,000 shares. Campbell Investment Adviser Ltd reported 13,590 shares or 0.36% of all its holdings. State Common Retirement Fund reported 595,427 shares. Nationwide Fund Advsr accumulated 33,848 shares. Cortina Asset Mgmt Ltd Company accumulated 0.44% or 1.22 million shares. Blackrock Advsr Lc owns 0% invested in NeoGenomics, Inc. (NASDAQ:NEO) for 28,528 shares.

Since May 25, 2017, it had 0 insider purchases, and 2 insider sales for $574,394 activity. The insider BALLIET JENNIFER sold $25,005.

NeoGenomics, Inc. (NASDAQ:NEO) Ratings Coverage

Among 10 analysts covering NeoGenomics (NASDAQ:NEO), 8 have Buy rating, 1 Sell and 1 Hold. Therefore 80% are positive. NeoGenomics has $11 highest and $8 lowest target. $10.07’s average target is -0.40% below currents $10.11 stock price. NeoGenomics had 16 analyst reports since September 3, 2015 according to SRatingsIntel. The stock of NeoGenomics, Inc. (NASDAQ:NEO) earned “Outperform” rating by William Blair on Sunday, September 6. The stock of NeoGenomics, Inc. (NASDAQ:NEO) earned “Buy” rating by Roth Capital on Friday, May 26. Cantor Fitzgerald initiated the stock with “Overweight” rating in Thursday, December 15 report. The company was reinitiated on Wednesday, May 11 by Roth Capital. The firm has “Buy” rating given on Friday, May 26 by Cantor Fitzgerald. The stock of NeoGenomics, Inc. (NASDAQ:NEO) has “Buy” rating given on Monday, October 26 by TH Capital. The stock has “Buy” rating by BTIG Research on Friday, May 26. As per Monday, September 11, the company rating was downgraded by BTIG Research. As per Thursday, September 3, the company rating was maintained by Roth Capital. On Wednesday, July 27 the stock rating was downgraded by BTIG Research to “Neutral”.

The stock increased 0.10% or $0.01 during the last trading session, reaching $10.11. About 292,937 shares traded. NeoGenomics, Inc. (NASDAQ:NEO) has declined 13.46% since September 13, 2016 and is downtrending. It has underperformed by 30.16% the S&P500.

NeoGenomics, Inc. is an operator of a network of cancer-focused genetic testing laboratories. The company has market cap of $802.61 million. The Firm operates in Laboratory Testing Segment. It currently has negative earnings. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.